Winner for the European Inventor Award 2019 for Immunoscore®, Dr Jérôme Galon is Research Director (first class) at Inserm and head of an Inserm laboratory (Integrative Cancer Immunology) at the Cordeliers Research Center in Paris, France.
He was trained as an immunologist at the Pasteur Institute and at the Curie Institute (Paris, France). Between 1997 and 2001 he worked at the NIH (National Institute of Health, Bethesda, USA) on functional genomics, bioinformatics and immunology on fundamental and clinical research. In 1999, he received the Fellow Award for Research Excellence at NIH (USA).
Since 2001 and his full-tenured position at INSERM, Dr Galon leads interdisciplinary research. Work in his laboratory on comprehensive analysis of the tumor-microenvironment and bioinformatics demonstrated that the adaptive immune reaction within the tumor was a better predictor of survival than traditional staging based on cancer's size and spread (N Engl J Med, Science, Science Transl Med, Cancer Res, JCO, Gastroenterology, Immunity, Nat Cancer Rev). Dr Galon defined the concept of cancer immune-contexture and the Immunoscore®, and is PI of the Immunoscore® worldwide consortium.
Dr Galon was awarded for his work on cancer research by the French Foundation (Schaeverbeke Award 2008), and the Medical Research Foundation (Rose Lamarca Award 2008). He received the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology (Cancer Research Institute, New York, USA 2010), and the National Academy of Science Award (Simone et Cino del Duca Cancer Research Award, 2011), the Award from the National Academy of Medicine (Gallet et Breton Award, 2011), Award from the French Society of Immunology (Jacques Oudin Award, 2014). He gave the Annual B. Benacerraf Lecture in Immunology (Harvard, USA, 2014).
Dr Galon received the European Inventor Award 2019 for Immunoscore®.
Jérôme Galon is a co-founder of HalioDx and the Chairman of its Scientific Advisory Board.
Dominique Bellet earned his Pharm.D. in 1973, his M.D. in 1982, and his Ph.D. in 1985. Since 1982, he has been appointed as physician in charge of clinical and research laboratories in comprehensive cancer centers and is specialized in the diagnosis and follow-up of cancers using tumor markers. At the present time, he is chief of the Oncobiology Laboratory at Institut Curie-Hôpital René Huguenin. He has been a member of the faculty at the Massachusetts General Hospital and a member of the Faculty at Harvard Medical School. In 1987, he was appointed Professor of Immunology at University Paris Descartes.
His main scientific interest is the characterization of biomarkers and the translation of basic research findings into clinical practices and new medicines.
His research groups have developed four tests for the diagnosis and follow-up of cancers, a test for the screening of Down’s syndrome and another one for the diagnosis of sepsis. During the last two decades, more than one hundred million patients benefited from these tests which are now performed by most laboratories in 90 different countries all over the world.
He is the author of 150 scientific publications and co-inventor of 19 patents.
Dr. Carlo Bifulco is a surgical pathologist, with subspecialty training in Molecular Genetic Pathology and Hematopathology, currently serving as the Director of Molecular Pathology and Pathology Informatics at the Providence Regional Laboratory and as Director of Translational Molecular Pathology at the Earle A. Chiles Research Institute in Portland, Oregon.
Prior to joining Providence Pathology, Dr. Bifulco served on the Pathology faculty at Yale University and completed fellowships in Oncologic Surgical Pathology and Molecular Genetic Pathology at Memorial Sloan Kettering Cancer Center.
His translational research work is focused on supporting the characterization of the tumor’s microenvironment through immunohistochemical and image analysis techniques.
Alexander M.M. Eggermont, Director General of Gustave Roussy Comprehensive Cancer Center, Cancer Campus Grand Paris, France.
Full Professor of Oncology (2012-20) (Classe Exceptionnelle) at the Paris-Sud University in Paris, France. Full Professor of Surgical Oncology (2003-2016) as well as Endowed Professor of International Networking in Cancer Research (2011-2020) at Erasmus University MC Rotterdam. He holds the Joseph Maisin Chair in Oncology at Catholic University of Louvain in Belgium. PhD in tumor immunology at Erasmus University Rotterdam (1987) and is a Fellow of the NCI Surgery Branch, USA.
Specialties: His clinical specialties include immunotherapy, melanoma, sarcoma and regional therapy techniques as well as general drug development. He is a past Chair of the EORTC Melanoma Group and current Chair of the Adjuvant Therapy Committee EORTC MG. His basic research experience is in tumor immunology, advanced in vivo imaging models and tumor pathophysiology.
Scientific Output: is the author or co-author of > 700 peer-reviewed publications, book chapters and monographs. 34 PhD theses have originated in his clinical, translational and basic research programs at the Erasmus University MC Rotterdam. H-index: 72; >24000 citations
Dr. Hamilton is a gastrointestinal and molecular pathologist, and Professor and Head of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center (UTMDACC) since 1998.
Dr. Hamilton has been involved in research and clinical applications of the molecular pathology of gastrointestinal neoplasms since 1982. Of his 312 peer-reviewed publications, 205 address this topic, including two of the earliest evaluations of genomics as prognostic markers in colorectal adenocarcinoma.
Dr. Hamilton is a member of the ECOG-ACRIN Leadership as Deputy Chair for Laboratory Science and a member of the Disease Oriented Committee/Modality Oriented Committee (DOC/MOC). He continues to participate as pathologist for the Gastrointestinal Committee and has served since 1992 as Chair of the Laboratory Science and Pathology Committee that has responsibility for the ECOG-ACRIN Central Biorepository and Pathology Facility, formerly the ECOG Pathology Coordinating Office, which is located at UTMDACC, and for other ECOG-ACRIN core biorepositories. He is an ECOG-ACRIN representative on the NCI Group Banking Committee. He serves as the Principal Investigator for UTMDACC as a Scientific Member in ECOG-ACRIN and as a Lead Academic Participating Site (LAPS) in NCTN. As a result of his experience and expertise, he will be able to carry out effectively his required participation for success of this grant application.
Dr. Melero Attended Medical School at Navarra University (Pamplona, Spain). He moved in 1989 to the Hospital Universitario de la Princesa (Madrid) where he completed his residency and earned a PhD in immunology working on Natural Killer cell receptors with Miguel López-Botet.
His work contributed to the functional identification of the KIRs, surface receptors that are key for the function of Natural Killer cells and subsets of T cells.Postdoctoral experience in the USA was focused in experimental tumor immunology. His work during this period was involved in understanding costimulation adn coinhibition in the cellular immune response against cancer. His work contributed to define immunological ignorance of tumor antigens and, more importantly, contributed decisively on T-cell costimulation via CD137 under the supervision of Lieping Chen and Karl E. Hellström.
These studies served to discover a potent therapeutic approach using immunostimulatory monoclonal antibodies in rodent models of cancer. In 1999 he was recruited by the University of Navarra (CIMA and Clínica Universitaria) where he serves as a full professor of immunology and leads a group working in translational tumor immunotherapy with emphasis in cell therapy, cytokine gene therapy and immunostimulatory mAbs.
The main focuses of his activity are immunotherapy clinical trials involving cell therapy and immunostimulatory monoclonal antibodies. Dr. Melero has been awarded the BIAL Prize of Medicine (Portugal, 2005) and other honors.
CEO of the comprehensive cancer. center Jean Perrin
Professor of pathology, head of the department of pathology and tumor biology /center Jean Perrin, Clermont-Ferrand, France
Head of the INCa molecular diagnosis platform, Centre Jean Perrin, France.
Director of the research Unit ERTICa (university of Auvergne UdA EA4677)
Elected member direction committee medical school of Clermont-Ferrand
Member of the strategic scientific committee of Unicancer
Vice president of the translational research group of Unicancer
260 peer reviewed publications, H index 42
Breast cancer, lung cancer, ovarian cancer, colorectal cancer, techniques, quality assurance, Neoadjuvant therapy, Biomarkers
Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona
Medical Oncology Department P. Vall d'Hebron 119-129 08035 Barcelona, Spain
Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently the Head of the Medical Oncology Department at the Vall d’Hebron University Hospital in Barcelona and the Director of the Vall d’Hebron Institute of Oncology.
He is also the head of the Gastrointestinal Tumors and Phase I Unit and is actively involved in translational research and pharmacodynamic phase I studies with molecular targeted therapies and related translational research, with a special focus on EGFR-family inhibitors and IGFR-PI3K-Akt-mTOR pathway inhibitors, and also in phase II and III studies with new chemotherapy agents in gastrointestinal tumors.
Dr. Tabernero is actively involved in different Editorial Boards including the Journal of Clinical Oncology, Clinical Cancer Research, Cancer Discovery, Clinical Colorectal Cancer and Annals of Oncology. He has (co)authored approximately 250 peer-reviewed papers.
Dr. Tabernero is a member of the Executive Board of the European Society for Medical Oncology (ESMO), currently holding the position of Treasurer and Chair of Audit Committee. He has been elected ESMO President 2018-2019 and serves as President-Elect from 2016. In addition, he is a member of the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO).
He has also been member of the Educational and Scientific Committees of the ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.